Once, I was told that my career pathway wouldn’t get me anywhere

“I needed to be this…”
“I should do that…”

We don’t have to fit in anybody’s box…

<5 years from fellowship

What to do after chemo-IO failure in #NSCLC ?
How can we beat 2L Docetaxel dogma?
1⃣ week before #ASCO24 , our chapter on ASCO Educational book is out, covering:
✅ Add-on strategies
✅ Targeted
✅ IO +TKIs
✅ ADCs
✅ Novel IO
✅ Toxicity

Don't miss our #ASCO24 session on

One degree hotter! 👨🏻‍🎓🩺 Thank you Kristen A. Marrone, MD for hooding me (and convincing me to stay in med school), and to all my other mentors I’m so lucky to have learned from Joseph Murray Katherine Chretien Rakhi Naik, MD MHS Lukasz Gondek JOSEPHINE FELICIANO Jarushka Naidoo Andi Shahu, MD MHS and so many more ❤️

Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy.
We may need to analyze timing of IO infusion in phase III trials to guide us in our daily clinic.
cell.com/cell/fulltext/…

🔥 off the press JTO & JTO CRR - EORTC LungTech trial 8×7.5Gy in central NSCLC
At 3-year
▶️freedom from local progression 81.5%
▶️distant progression 29.8%
▶️SBRT-related acute and late AEs ≥ G3 in 6.5% and 19.4 %
jto.org/article/S1556-…

Ph III trial methylphenidate v pbo for cancer fatigue in adv solid tumors Journal of Clinical Oncology:

- 162pts, 14% NSCLC
- MPD dose, max 20mg tds
- no diff primary endpt (FACIT-F), or QOL at 6wks

Ideal MPD dose & primary endpt challenging to identify
OncoAlert #LCSM ascopubs.org/doi/10.1200/JC…

Thanks Irish Cancer Society for including a familiar face in their new TV ad!

Thanks to this dynamic society for funding my research & others. Your support has led to real progress for patients

Beaumont RCSI Cancer Centre RCSI Research and Innovation Beaumont Hospital #IrishLungCancerAlliance #IrishLungCancerCommunity #LCSM

jtocrr.org/article/S2666-…

Thanks to JTO & JTO CRR for publishing this informative case report illustrating successful rechallenge of lorlatinib after grade 4 psychosis from our team The Royal Marsden NHS Foundation Trust led by Alexius John and Sanjay Popat

🚨HUGE victory for SCLC!🚨

FDA Oncology, under Project Orbis and the FDA Center of Excellence, grants accelerated APPROVAL for tarlatamab (Imdelltra, DLL3 BiTE) Amgen Oncology for relapsed small cell lung cancer after platinum-based therapy!

#LCSM SmallCellSMASHERS The Shields Lab

Prof Jarushka Naidoo Jarushka Naidoo discussed recent progress in #LungCancer including precision medicine, immunotherapy and genetics.

She highlighted how understanding populations is key to bringing this progress to patients.

#CancerCareForAll2024 RCSI Beaumont Hospital

Ph III CM77T trial NEJM: Periop Nivo in Stage IIA-IIIB NSCLC:

- neoadj nivo+chemo x 4 + 1yr adj nivo v neoadj chemo x 4 + 1yr adj pbo
- EFS HR 0.58 (p<0.001), pCR 25.3% v 4.7% favoring nivo+chemo
- g3+ TRAEs in 32.5% v 25.2%

#TCascone @Oncoalert #LCSM
nejm.org/doi/full/10.10…

Join us for an insightful discussion on evolving therapies in NSCLC led by 🌟 fellows Jennifer Marks, MD and Michael Conroy at the #LungCancerSymposiun tmrw 5/16 at Joe Theisman's Restaurant & Bar. Georgetown Lombardi Johns Hopkins Thoracic Oncology Susan Combs Scott, MD Georgetown Hematology/Oncology Fellowship

Outstanding presentation about the growth of #LungCancer research and Trials by Jarushka Naidoo #IrishLungCancerAlliance CancerTrialsIreland 🌈
An overlooked area for decades to now being able to offer a comprehensive trials across the disease bringing in the wider research community

Interesting multi-omic analysis of previously classified SCLC cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis

Clinical Cancer Research OncoAlert #LCSM

aacrjournals.org/clincancerres/…

Wishing a Happy Birthday to Jeffrey Weber MD today. So important to the field of Immunotherapy. An amazing friend, mentor, leader.
NYU Langone Health Society for Immunotherapy of Cancer ASCO ESMO - Eur. Oncology

I am very excited to serve as track chair for early stage NSCLC and other thoracic tumours at #ESMO24

📆 Abstract closing date is tomorrow! ⏰ 5pm CET

Submit your important work here👇
🔗ow.ly/hyT350RgeC2

Andres Cervantes Rebecca Dent FabriceAndre Solange Peters ESMO - Eur. Oncology

An elegant presentation by Stephen V Liu, MD regarding synergy between immunotherapy and ADCs which could change lung cancer option’s treatment. #InnovativeCancerTherapies #RomeLung24

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC . w/ a stellar faculty Jordi Remon Solange Peters Francesco Christian Rolfo, Tony Mok Stephen V Liu, MD, Fred R. Hirsch Federico Cappuzzo Roberto Ferrara Benjamin Besse &